Speaking of other trials they didn’t flag any requirement for further funding for a phase 3 trial for HNSCC in any of their cap raise talks.
So this will lead to one of two things:
1. No further requirement for funding in this matter, which points to the trial data being negative
2. IMM extending their hands for more funding in the short term to fund another phase 3.
But the shareholders would hope a licensing deal will prevail over the two things I’ve mentioned.
Ann: Immutep completes institutional pro-rata offer & placement, page-33
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |